- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
A study accepted to ML4H 2025 explores whether sequence-based models trained on large-scale T-cell activation data can improve prediction of T cell receptor recognition, a longstanding challenge in computational immunology with implications for cancer and autoimmune disease. Predicting how T-cell receptors (TCRs) recognize peptide–MHC (pMHC) antigens is one of the central challenges in immunology today. It […] The post Predicting T Cell Recognition: New Insights from Large-Scale Activation Data appeared first on Adaptive Biotech.
The Human Rights Campaign (HRC) Foundation’s 2025 Corporate Equality Index (CEI) is the national benchmark on corporate policies, practices and benefits impacting LGBTQ+ employees. Each year, the CEI is a primary driving force for LGBTQ+ workplace inclusion and provides a valuable and objective score in the adoption of critical measures of an employer’s commitment to […] The post Adaptive Earns Cornerstone Recognition for LGBTQ+ Workplace Inclusion in HRC’s 2025 Corporate Equality Index appeared first on Adaptive Biotech.
Facing cancer takes courage. It also requires collaboration: patients and their physicians working together to gain the information they need throughout the treatment journey. At Adaptive, we are proud to develop advanced testing methods that can provide these insights as patients and their care teams manage blood cancer care. In honor of the important relationships […] The post Jim’s Journey: The Power of Collaboration in Blood Cancer Care appeared first on Adaptive Biotech.
Pride Month is an opportunity to celebrate the history and progress made by the lesbian, gay, bisexual, transgender, queer (LGBTQ+) community, while also reflecting on the ongoing challenges faced today. As the lead of the Adaptive Pride employee resource group (ERG), we arranged exciting programming with onsite lunches, social events, and speaking engagements focused on how […] The post Pride Month at Adaptive: Celebrating Progress and Community appeared first on Adaptive Biotech.
In the ever-evolving field of immunology, the study of T-cell responses to various exposures is pivotal for unraveling the complexities of immune health and advancing new therapies that use these natural defenses. T cells, through their unique receptors, record the history of an individual’s immune challenges, such as infections, vaccinations or various chronic conditions, referred […] The post Decoding Public T-cell Signatures of Disease with Tens of Thousands of T-cell Receptor Repertoires appeared first on Adaptive Biotech.
In honor of Multiple Myeloma Awareness Month, we sat down with Dr. Hamza Hashmi, a hematologist-oncologist from Memorial Sloan Kettering Cancer Center, to understand how his family’s personal experience with cancer has influenced his approach to treating and caring for patients living with myeloma and other plasma cell disorders. As an oncology specialist, Dr. Hashmi […] The post When the Doctor Becomes the Caregiver appeared first on Adaptive Biotech.
In 2021, Susan Bobulsky sat down with Dr. Luciano Costa to learn about the initial results from the phase 2 MRD response-Adapted Sequential ThERapy (MASTER) trial. The trial evaluated daratumumab (Darzalex), carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Dara-KRd) as induction therapy in patients with newly diagnosed multiple myeloma (MM), followed by autologous stem cell transplant (ASCT) and […] The post Clinically Actionable Insights: A Q&A with Dr. Luciano Costa on the Final Analysis of MASTER appeared first on Adaptive Biotech.
Adaptive Immunosequencing provided critical insight into the T-cell response elicited by the vaccine, and its correlation with delayed disease recurrence. The post Immune Medicine in Action: How Adaptive Immunosequencing Helped Validate a Personalized Vaccine Trial in PDAC appeared first on Adaptive Biotech.
Adaptive is dedicated to recognizing patients like Tiffany and to contribute to the world’s understanding of the critical role that MRD can play in blood cancer patient care. The post Hope restored: The critical role that Minimal Residual Disease can play in blood cancer patient care appeared first on Adaptive Biotech.
MRD testing can help to provide an accurate, ongoing picture of disease and risk status, offering a sense of control and comfort during a time when life may feel less manageable. The post Among Multiple Myeloma Patients Receiving MRD Testing, Majority Report Meaningful Benefits appeared first on Adaptive Biotech.
